By Naimul Karim, Thomson Reuters Foundation
3 Min Read
DHAKA, April 16 (Thomson Reuters Foundation) - Mim Akter had to walk for nearly an hour before she found a rickshaw to take her to the garment factory where she works in locked-down Dhaka this week.
With public transport in the Bangladeshi capital stopped, factory owners were supposed to provide transport for their staff. But many did not, leaving workers to walk long distances or pay many times the normal fare to travel to work.
“The usual charge is 10 taka, but I was charged 30,” said Akter, 31, who has two children and barely gets by on her monthly salary of 9,000 taka ($106).
Ruma Paul, Krishna N. Das
2 分钟阅读
DHAKA/NEW DELHI, Jan 11 (Reuters) - Serum Institute of India will sell the AstraZeneca coronavirus vaccine to Bangladesh at $4 a dose, three sources with knowledge of the mater told Reuters, about 47% more than India will pay for its inoculation campaign.
The pricing for Bangladesh, the world’s eighth-most populous country, provides a first glimpse of what it will cost other low- and middle-income countries that are seeking to secure the vaccine developed by British drugmaker AstraZeneca with Oxford University.
Bangladesh, a country of more than 160 million people, in November signed a preliminary agreement to buy 30 million doses of the shot from Serum - the world’s biggest vaccine maker by volume.